UroAlert - GU Oncology Weekly

October 23, 2025

Videos

Peer-to-Peer Clinical Conversations

Analysis of MRI Use in the Diagnostic Pathway for Bladder Cancer - Nicholas James

Nicholas James

Nicholas James discusses final BladderPath trial survival analyses with Ashish Kamat, demonstrating multiparametric MRI introduced upstream of TURBT significantly improves bladder cancer-specific survival with statistically significant hazard ratio driven entirely by muscle-invasive disease outcomes.

Metastasis-Directed Therapy for Low-Volume mHSPC - Luis Salgado

Luis Salgado

Zachary Klaassen hosts Luis Salgado to discuss metastasis-directed therapy for low-volume hormone-sensitive prostate cancer.

Conference Coverage

ESMO 2025: Perioperative Chemo-Immunotherapy with Durvalumab for Operable Muscle-Invasive Urothelial Carcinoma (MIUC): Final Analysis of the Single Arm Phase II Trial SAKK 06/17

ESMO 2025: Optimal Treatment Duration in Metastatic Renal Cell Carcinoma Patients Responding to Immune Checkpoint Inhibitors: Should We Treat Beyond Two Years?

ESMO 2025: Impact of Dose Reductions on the Efficacy of Erdafitinib in Patients with Advanced or Metastatic Urothelial Carcinoma (mUC): A Post-hoc Analysis of the Phase 3 THOR Study Cohort-1 Evaluating Erda versus Chemotherapy (Chemo)

ESMO 2025: Targeting Androgen Receptor Alterations in Prostate Cancer

ESMO 2025: Optimizing Patient Selection for Radioligand Therapy in Advanced Stages

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial

Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial

Management of bladder cancer recurrence following the trimodality therapy.

Beyond Visualization: Advanced Imaging, Theragnostics and Biomarker Integration in Urothelial Bladder Cancer.

Clinical Predictors and Prognostic Significance of Pathologic Disease Upstaging at Radical Cystectomy in Patients with Muscle-Invasive Bladder Cancer.

Contemporary Trends and Predictors of pT0 in Radical Cystectomy Specimens Among Non-Muscle and Muscle-Invasive Bladder Cancer Patients: A Propensity Score-Matched Analysis from a Single Tertiary Centre in the United Kingdom.

The hypoxic ECM and neutrophils in MIBC immunotherapy resistance.

Online adaptive radiation therapy for muscle-invasive bladder cancer: short-course and high-precision definitive treatment for elderly or medically fragile patients.

Dabogratinib (TYRA-300), an FGFR3 isoform-selective inhibitor: preclinical and initial clinical evidence of anti-tumor activity.

A Novel Heterologous Prime-boost Strategy Using RUTI Vaccine to Improve the Bacillus Calmette-Guérin Response in Non-muscle-invasive Bladder Cancer Patients: Phase 1 RUTIVAC-1 Trial.

Intermediate-risk Non-muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group.

Persistent Sex Disparities in Bladder Cancer Diagnosis, an Analysis of National Trends from 2012 to 2021.

Penile & Urethral Cancers

Penile cancer in French Guiana: Epidemiology, histopathology and clinical aspects.

Navigating Penile Metastases: Personalized Management in a Rare Oncologic Challenge.

Magnetic sentinel node biopsy with Sienna+®/SentiMag® in penile squamous cell carcinoma: Case report.

Renal Cancer

FAP Expression in Renal Tumors Assessed by [68Ga]Ga-FAPI-46 PET Imaging and FAP Immunohistochemistry: A Case Series of Six Patients from the Prospective Exploratory Trial NCT04147494.

Cambridge kidney One-Stop Mass Investigation Clinic (CkOSMIC): A Nonrandomised Feasibility Study.

Local Recurrence After Nephron Surgery: What to Do? An Italian Multicentric Registry.

A Review of Immunotherapy in Renal Cell Carcinoma: Current Landscape and Future Directions.

CABOSEQ 3-Comparison of Cabozantinib versus Sunitinib Following First-Line Nivolumab- Ipilimumab for Metastatic Renal Cell Carcinoma: A Target Trial Emulation Using Real-World Data from the International Metastatic Renal Cell Carcinoma Database Consortium

Real World Efficacy of 1st-Line Nivolumab Plus Ipilimumab and its Practical Predictive Biomarkers in Advanced Renal Cell Carcinoma: First Analysis from RENOIR Study (KCSG GU22-13).

Postimmunotherapy and Vascular Endothelial Growth Factor Inhibitor Landscape in Advanced Renal Cell Carcinoma: Treatment Patterns, Costs, and Outcomes.

Real-world outcomes of immune checkpoint inhibitor-based combination therapy in older adult patients with metastatic renal cell carcinoma: a multi-center, retrospective analysis.

Same day discharge after robot assisted partial nephrectomy.

Circulating Kidney Injury Molecule-1 (KIM-1) and Association with Outcome to Adjuvant Immunotherapy in Renal Cell Carcinoma- Beyond the Abstract

End-of-Life and Palliative Care in Patients with Metastatic Renal Cancer - Beyond the Abstract

Postoperative mortality in renal cell carcinoma with vena cava thrombus in the elderly population (uroCCR study n°192).

Prostate Cancer

Disparities in MRI and TRUS for Prostate Cancer Detection: A Systematic Review and Meta-Analysis of 94,020 Cases - Beyond the Abstract

PSMAddition Data Show Novartis Pluvicto™ Delays Progression to End-Stage Prostate Cancer

Prognostic Value of AI-Assisted Lesion Tracking on End-of-Treatment PSMA PET in mCRPC Patients Treated with 177Lu-PSMA: A Retrospective, Single-Center Study - Beyond the Abstract

Innovative Se-Flutamide Derivatives: Enhanced Activity Toward Androgen Receptor (AR)-Dependent and -Independent Prostate Cancer Cells.

Modelling of immune infiltration in prostate cancer treated with HDR-brachytherapy using Raman spectroscopy and machine learning.

Active Monitoring, Surgery, and Radiotherapy for Cribriform-Positive and Cribriform-Negative Prostate Cancer: A Secondary Analysis of the PROTECT Randomized Clinical Trial.

PSMA PET Evaluation with a Deep Learning Platform Compared with a Standard Image Viewer and Histopathology.

Impact of PSMA PET Staging on Initial Treatment in Newly Diagnosed Prostate Cancer.

Urinary quality of life in patients treated with prostate SBRT with intra-prostatic boost.

Longitudinal outcome prediction of prostate cancer patients on active surveillance using multiple instance learning.

Seven-Year PSA ≤ 0.2 ng/mL After High-Dose-Rate Brachytherapy Indicates Eligibility for Discontinuing PSA Surveillance in Prostate Cancer.

Multi-layer stratified oncology platform utilizing transcriptomics, prostate cancer organoids, and modeling of drug response.

Quality of life in low-risk prostate cancer under active surveillance or following radical treatments: the START cohort study.

UK real-world data of radium-223 dichloride in metastatic prostate cancer.

Time and cost burden associated with docetaxel in patients with metastatic castration-sensitive prostate cancer initiating an androgen receptor pathway inhibitor-based regimen.

Experiences of metastatic prostate cancer patients with a mainstream genetic testing pathway.

The Conundrum of Intermediate Risk in Localised Prostate Cancer: One Group, Many Realities.

Informing the development of a nurse-led survivorship intervention for men with prostate cancer treated with androgen deprivation therapy: A qualitative exploratory study.

A Social Media Campaign and Web-Based Survey About Prostate Cancer Genetics: Mixed Methods Study.

Real-world treatment patterns and survival outcomes in patients with metastatic castration-resistant prostate cancer in France: lessons from the prospective OPALE study.

Experience of uncertainty in prostate cancer: A qualitative study.

Differences in prostate cancer treatment receipt and timeliness of treatment between African American/Black and White Iowans.

Oncological outcomes after tailored PSMA-PET-guided treatment in biochemical relapse after prostatectomy (PSICHE Trial-NCT 05022914).

Liquid biopsy identifies taxane resistance and clonal selection in castration-resistant prostate cancer.

Readability of Prostate Cancer Patient Education Materials: A Comprehensive Assessment Using Readability Metrics.

Utility of MRI perilesional biopsy in prostate cancer: impact of the Prostate Imaging-Reporting and Data System and biopsy history.

Prediction of Metastasis-Free Survival in Patients with Localized Prostate Adenocarcinoma Using Primary Tumor and Lymph Node Radiomics from Pre-Treatment PSMA-PET/CT Scans - Beyond the Abstract

Integrating systemic therapy and metastasis-directed therapy in oligometastatic hormone-sensitive prostate cancer.

IP8-FLUORESCE: A Prospective Paired Cohort Study Evaluating the Diagnostic Accuracy of Fluorescence Confocal Microscopy for Real-time Assessment of Surgical Margins in Radical Prostatectomy.

Understanding Management Strategies for Metastatic Hormone-Sensitive Prostate Cancer: A Multidisciplinary Survey in France.

Upper Tract Tumors

Systematic biopsies of the upper urinary tract: a tool to improve the diagnostic accuracy of ureteroscopy and characterization of upper tract urothelial cancer.

Adjuvant Chemotherapy and Immunotherapy in Upper Tract Urothelial Carcinoma: Where Do We Stand?

Kidney-sparing approach for upper tract urothelial carcinoma: An update on current evidence.

Testicular Cancer

Insights From Testicular Cancer Deaths in the U.S. Military: Case Reports.

Prostatic Metastasis of Bilateral Metachronous Testicular Cancer: A Case Report and Review of the Literature.

Epidemiological patterns, temporal trends in management and long-term outcomes in testicular cancer: a 30-year single center experience.

Immunohistochemical Expression of Nectin-4 and Potential Implications for Enfortumab Vedotin Therapy in Germ Cell Tumors of the Testis: A Preliminary Study - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2025 Digital Science Press, LLC